Medicus Pharma's 'Savvy' Antev Deal De-Risks Pipeline Expansion, Enhances Near-Commercial Portfolio
1. MDCX to acquire Antev, boosting pipeline in men's health. 2. Teverelix targets $2 billion market for AUR treatment. 3. Analyst raised target price from $14 to $27 for MDCX. 4. Positive interim phase 2 results for D-MNA treatment announced. 5. MDCX stock rose 15.8% to $5.31 following news.